A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Trial Profile

A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Abituzumab (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms STRATUS
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Feb 2018 Status changed from recruiting to discontinued.
    • 06 Feb 2018 This trial has been Discontinued in Spain (end date: 2018-01-17)
    • 18 Dec 2017 Planned End Date changed from 17 Dec 2019 to 31 Oct 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top